SFDA Alerts On Adverse Reactions Of Aciclovir And Cephradine
This article was originally published in PharmAsia News
China's State FDA has alerted health care professionals, pharmaceutical manufacturers and distributors and the public about adverse reactions associated with antiviral aciclovir and antibiotic cephradine. According to figures from the National Center for ADR Monitoring, problems attributed to the two drugs - acute renal impairment and blood in urine - are still outstanding. SFDA reminds physicians to conduct full risk-benefit analysis when choosing drugs, paying especially close attention to the adverse effects caused by aciclovir and cephradine. The relevant manufacturers should conduct in-depth research into the mechanisms of the drug-caused impairment, evaluate the overall risk-benefit of the two medicines and adopt timely effective measures to reduce recurrence of adverse incidents in similar drugs. (Click here for more - Chinese Language)
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.